Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs17174393
rs17174393
A 0.700 CausalMutation CLINVAR

dbSNP: rs121913500
rs121913500
0.050 GeneticVariation BEFREE En bloc resection revealed a high-grade glioma with sarcomatous components that was immunoreactive for the R132H variant of IDH1 by antibody. 27153165

2017

dbSNP: rs121913500
rs121913500
0.050 GeneticVariation BEFREE In malignant glioma the presence of the IDH1 mutation (IDH1(R132H)) is associated with better clinical outcome. 26328938

2015

dbSNP: rs121913500
rs121913500
0.050 GeneticVariation BEFREE Isocitrate dehydrogenase 1 gene (IDH1) R132H mutation status was also recently identified as a prognostic factor for malignant gliomas. 24929863

2014

dbSNP: rs121913500
rs121913500
0.050 GeneticVariation BEFREE We highlight the importance of Sox11 expression as a favourable prognosticator in glioblastomas. c-Met/nestin/IDH1-R132H expression phenotypes recapitulate the molecular subgroups of malignant glioma. 23619925

2013

dbSNP: rs121913500
rs121913500
0.050 GeneticVariation BEFREE Of 158 tumors with sufficient tissue, 110 (70 %) showed nuclear cMYC immunopositivity--most frequent (95 %, χ(2) p = 0.0248) and intense (mean 1.33, ANOVA p = 0.0179) in anaplastic astrocytomas versus glioblastomas (63 %) or low grade gliomas (74 %). cMYC expression associated with younger age as well as p53 immunopositivity (OR = 3.6, p = 0.0332) and mutant IDH1 (R132H) (OR = 7.4, p = 0.06) among malignant gliomas in our cohort. 23934175

2013

dbSNP: rs113488022
rs113488022
0.030 GeneticVariation BEFREE In summary, high grade astrocytomas with BRAF V600E, ATRX, and CDKN2A/B alternations had unique clinicopathological features and may be a novel subset of high grade glioma. 30972500

2019

dbSNP: rs121913377
rs121913377
0.030 GeneticVariation BEFREE In summary, high grade astrocytomas with BRAF V600E, ATRX, and CDKN2A/B alternations had unique clinicopathological features and may be a novel subset of high grade glioma. 30972500

2019

dbSNP: rs113488022
rs113488022
0.030 GeneticVariation BEFREE Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. 29039591

2017

dbSNP: rs121913377
rs121913377
0.030 GeneticVariation BEFREE Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. 29039591

2017

dbSNP: rs113488022
rs113488022
0.030 GeneticVariation BEFREE Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma. 27799506

2016

dbSNP: rs121913377
rs121913377
0.030 GeneticVariation BEFREE Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma. 27799506

2016

dbSNP: rs1920116
rs1920116
0.020 GeneticVariation BEFREE A recent genome-wide association study has identified an association between rs1920116 near TERC and high-grade glioma in populations of European ancestry. 26017031

2015

dbSNP: rs1920116
rs1920116
0.020 GeneticVariation BEFREE Here we identify a new SNP associated with glioma risk, rs1920116 (near TERC), that reached genome-wide significance (Pcombined = 8.3 × 10(-9)) in a meta-analysis of genome-wide association studies (GWAS) of high-grade glioma and replication data (1,644 cases and 7,736 controls). 24908248

2014

dbSNP: rs1057519902
rs1057519902
0.010 GeneticVariation BEFREE Extraneural Metastases From a High-Grade Glioma (HGG) With an H3F3A G34R Mutation. 31139567

2019

dbSNP: rs117677079
rs117677079
0.010 GeneticVariation BEFREE We found that rs117677079 polymorphism was strongly associated with an increased risk of glioma (OR 1.64, p = 0.003) and a worse prognosis for glioma, especially in high-grade glioma (HR 1.76, p = 0.005). 30536196

2019

dbSNP: rs1553260624
rs1553260624
0.010 GeneticVariation BEFREE Extraneural Metastases From a High-Grade Glioma (HGG) With an H3F3A G34R Mutation. 31139567

2019

dbSNP: rs2239647
rs2239647
0.010 GeneticVariation BEFREE We found that rs2239647 polymorphism was strongly associated with an increased risk of glioma (OR = 1.90, p = 0.007) and a worse prognosis for glioma, especially in high-grade glioma (HR = 1.67, p = 0.034). 31759389

2019

dbSNP: rs1057519903
rs1057519903
0.010 GeneticVariation BEFREE A case report of adult cerebellar high-grade glioma with H3.1 K27M mutation: a rare example of an H3 K27M mutant cerebellar tumor. 29264735

2018

dbSNP: rs1057519904
rs1057519904
0.010 GeneticVariation BEFREE A case report of adult cerebellar high-grade glioma with H3.1 K27M mutation: a rare example of an H3 K27M mutant cerebellar tumor. 29264735

2018

dbSNP: rs12917
rs12917
0.010 GeneticVariation BEFREE Logistic regression analysis showed that Leu84Phe of MGMT gene and pathological grade were independent risk factors for the increase of TMZ resistance in patients with malignant gliomas. 28409559

2017

dbSNP: rs1424913115
rs1424913115
0.010 GeneticVariation BEFREE Logistic regression analysis showed that Leu84Phe of MGMT gene and pathological grade were independent risk factors for the increase of TMZ resistance in patients with malignant gliomas. 28409559

2017

dbSNP: rs2308321
rs2308321
0.010 GeneticVariation BEFREE This study aims to investigate the associations of O<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT) genetic polymorphisms (Leu84Phe and Ile143Val) with temozolomide (TMZ) resistance and prognosis of patients with malignant gliomas. 28409559

2017

dbSNP: rs2252586
rs2252586
0.010 GeneticVariation BEFREE Similarly, stratified analysis of rs2252586 by stages revealed the similar trend, with OR of 1.26 (95 %CI = 1.17-1.35) in high-grade glioma and OR of 1.15 (95 %CI = 1.08-1.22) in low-grade glioma. 26243184

2016

dbSNP: rs7502563
rs7502563
0.010 GeneticVariation BEFREE Stratified analyses indicated that the association between rs7502563 and glioma was more pronounced in females (OR = 0.40, 95 % CI = 0.20-0.80, P = 0.0091), older subjects (OR = 0.47, 95 % CI = 0.26-0.86, P = 0.0135), and subjects with high-grade glioma (OR = 0.45, 95 % CI = 0.27-0.77, P = 0.0031). 26361958

2016